| Symbol
| NR5A2
| contributors: mct - updated : 19-02-2018
|
| HGNC name
| nuclear receptor subfamily 5, group A, member 2
|
| HGNC id
| 7984
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
in breast cancer cell lines expressing ESR1 | | tumoral
|
|
|
| gain of function
|
in pancreatic cancer cells compared to normal pancreatic ductal epithelium  | | tumoral
|
|
| --over
|
| |
in pancreatic tumors | |
| Susceptibility
|
to inflammatory bowel disease (IBD) |
| Variant & Polymorphism
| protective role against the onset of IBD, intimately linked with its commanding role on glucocorticoid synthesis in the intestinal epithelium |
| 
|
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | endocrine | pancreas | |
| might be a plausible therapeutic target for treatment of pancreatic cancer | | cancer | | | |
| targeting NR5A2 may provide an attractive prospect for treatment of tumors that are resistant to hormonal and targeted therapy |
| | | |